Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (271-280 of 333) with videos related to

Pageof 34
Sort By:
Circulation|March 29, 2025
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized TrialNikolaus Marx, John E Deanfield, Johannes F E Mann, et al.
Plos One|June 1, 2014
Mutation in KERA identified by linkage analysis and targeted resequencing in a pedigree with premature atherosclerosisStephanie Maiwald, Suthesh Sivapalaratnam, Mahdi M Motazacker, et al.
JAMA Internal Medicine|February 2, 2026
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical TrialRodica Pop-Busui, Søren Rasmussen, John E Deanfield, et al.
The Lancet. Diabetes & Endocrinology|June 2, 2016
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaul D Santos, Samuel S Gidding, Robert A Hegele, et al.
Pharmacogenomics|April 6, 2016
A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol loweringMaarten Leusink, Anke H Maitland-van der Zee, Bo Ding, et al.
European Journal of Preventive Cardiology|February 13, 2021
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI studyKausik K Ray, Bart Molemans, W Marieke Schoonen, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
Nature Medicine|August 27, 2023
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trialBarry A Borlaug, Dalane W Kitzman, Melanie J Davies, et al.
Cell Metabolism|December 14, 2011
Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in manAdriaan G Holleboom, Helen Karlsson, Ruei-Shiuan Lin, et al.
Pageof 34

Showing results (271-280 of 333) with videos related to

Sort By:
Pageof 34
Circulation|March 29, 2025
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized TrialNikolaus Marx, John E Deanfield, Johannes F E Mann, et al.
Plos One|June 1, 2014
Mutation in KERA identified by linkage analysis and targeted resequencing in a pedigree with premature atherosclerosisStephanie Maiwald, Suthesh Sivapalaratnam, Mahdi M Motazacker, et al.
JAMA Internal Medicine|February 2, 2026
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical TrialRodica Pop-Busui, Søren Rasmussen, John E Deanfield, et al.
The Lancet. Diabetes & Endocrinology|June 2, 2016
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaul D Santos, Samuel S Gidding, Robert A Hegele, et al.
Pharmacogenomics|April 6, 2016
A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol loweringMaarten Leusink, Anke H Maitland-van der Zee, Bo Ding, et al.
European Journal of Preventive Cardiology|February 13, 2021
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI studyKausik K Ray, Bart Molemans, W Marieke Schoonen, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
Nature Medicine|August 27, 2023
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trialBarry A Borlaug, Dalane W Kitzman, Melanie J Davies, et al.
Cell Metabolism|December 14, 2011
Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in manAdriaan G Holleboom, Helen Karlsson, Ruei-Shiuan Lin, et al.
Pageof 34